Cardiovascular disease is the main cause of death in patients with rheumatoid arthritis. In this editorial Michael Nurmohamed discusses the EULAR recommendations for cardiovascular risk management, focusing on the role of the rheumatologist.
Understanding and treatment of rheumatoid arthritis has changed dramatically over the past two decades. Peter Taylor describes the impact of biologic tumor necrosis factor inhibitors on the management of this disease.
Patients who are treated with ibuprofen alone experience comparable pain control in the first day after hip replacement to those give acetaminophen plus ibuprofen, findings from the PANSAID trial suggest.
A Finnish trial has shown no significant improvement in the outcomes of patients with early rheumatoid arthritis who are monitored using an automated text message-enhanced approach versus the standard approach.
Patients with ankylosing spondylitis have a significantly increased risk for venous thromboembolism compared with the general population, with the risk apparently highest in the first year after diagnosis, study findings indicate.
Patients who are treated with ibuprofen alone experience comparable pain control in the first day after hip replacement to those give acetaminophen plus ibuprofen, findings from the PANSAID trial suggest.
Cardiovascular disease is the main cause of death in patients with rheumatoid arthritis. In this editorial Michael Nurmohamed discusses the EULAR recommendations for cardiovascular risk management, focusing on the role of the rheumatologist.
Findings from a multi-database study suggest that rheumatoid arthritis patients treated with tocilizumab do not have a higher overall risk for serious infection than those treated with tumor necrosis factor inhibitors, but their risk for certain types of infection may be elevated.
medwireNews takes a look at the efficacy and safety profiles of JAK inhibitors for the treatment of rheumatoid arthritis, and addresses some common questions about their use.
Inflammatory bowel disease is an “uncommon” occurrence among patients with psoriatic arthritis, ankylosing spondylitis, or psoriasis who are treated with the interleukin-17A inhibitor secukinumab, researchers report.
Patients with rheumatoid arthritis have better outcomes when treated with rituximab or tocilizumab than abatacept or tumor necrosis factor inhibitors, suggest the results from two real-world studies.
Findings from a systematic review suggest that methotrexate may offer some benefits for patients with psoriatic arthritis, but the quality of evidence is low.
